Nelson Handal, MD
Child & Adolescent Psychiatry · Dothan, ALNPI 1154471548
Payments from drug & device makers
Across 1,114 payments — averaging $2263.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$524K
- F. Hoffmann-la Roche AG$351K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$344K
- Sage Therapeutics, LLC$212K
- Genentech, Inc.$181K
- Janssen Research & Development, LLC$176K
- plus $733K from 34 others
Across 20 payments — averaging $181.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
What the payments were for
- Consulting fees$21,17026%
- Speaking & faculty fees$37,55547%
- Travel & lodging$7,62510%
- Food & beverage$10,95114%
- Education$920%
- Other$2,8094%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Azstarys$34,229
- QUVIVIQ$9,599
- QELBREE$6,225
- Jornay PM 20mg capsules (Bottle of 100)$4,763
- NEUROSTAR TMS THERAPY SYSTEM$2,809
- CAPLYTA$1,980
- Non-Covered Product$1,780
- LYBALVI$443
- Fanapt$232
- VRAYLAR$125
- SPRAVATO$121
- Dyanavel XR$118
- Quillivant$118
- Quillichew ER$118
- NEUROSTAR TMS THERAPY$107
How this compares
$2,521,410 in reported general payments places this provider in the 95th percentile of 40 child & adolescent psychiatry providers in Alabama.
See all child & adolescent psychiatry providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 42 | $61,889 |
| SpravatoEsketamine Hcl | 27 | $26,896 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $13,644 |
| LamictalLamotrigine | 20 | $13,043 |
| QuviviqDaridorexant Hcl | 25 | $12,089 |
| Lisdexamfetamine Dimesylate | 48 | $9,120 |
| Jornay PmMethylphenidate Hcl | 13 | $5,949 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 47 | $4,727 |
| Lurasidone Hcl | 27 | $4,237 |
| Asenapine Maleate | 11 | $3,454 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 39 | $3,129 |
| Aripiprazole | 53 | $2,662 |
| Dextroamphetamine Sulfate | 22 | $2,367 |
| Naltrexone Hcl | 15 | $2,243 |
| Trazodone Hcl | 90 | $1,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $523,677 | $61,88942 claims |
| Johnson & JohnsonSpravato | $1,247 | $26,89627 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $18,532 | $13,64436 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $9,963 | $12,08925 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $5,360 | $5,94913 claims |
| Almatica Pharma LLCSertraline Hcl | $506 | $31142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 40 child & adolescent psychiatry providers in Alabama.
Other child & adolescent psychiatry in Dothan
- Jerlyn McCleodDothan$9K
- Artie NelsonBirmingham$32K
- Karen CallahanBirmingham$5K
- Curtis AdamsHuntsville$5K
- Casey LowreyBirmingham$4K
- Aparna VuppalaHuntsville$3K
- Richard SinclairMobile$2K
- John Broderick-CantwellDaphne$2K
- Christiana WilkinsOpelika$1K
- Elizabeth FergusonBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.